Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Rani Therapeutics Holdings, Inc. (RANI), with a market capitalization of $75 million, has experienced a significant downturn, with its stock price touching a 52-week low of $1.29. This latest price level reflects a stark contrast to the company's performance over the past year, which has seen the stock plummet by 60.42%. Investors are closely monitoring Rani Therapeutics as it navigates through a challenging period, with InvestingPro analysis indicating the company is quickly burning through cash and maintaining a weak financial health score. While market sentiment appears cautious, analyst price targets range from $8 to $17, suggesting potential upside. The 52-week low serves as a critical indicator for the stock's trajectory and potential turning points in the market's valuation of the biotech firm. (Discover 8 more exclusive insights about RANI with InvestingPro.)
In other recent news, Rani Therapeutics has made significant strides in its operations. The company reported encouraging preclinical pharmacokinetic data for its obesity treatment candidate, which uses a novel delivery method similar to its proprietary RaniPill technology. Rani Therapeutics also reported a Q2 net loss of $0.51 per share, consistent with expectations.
These developments are accompanied by a collaboration with South Korean biotech firm, ProGen Co., Ltd., to co-develop and commercialize RT-114, an oral therapeutic for obesity. The two companies have agreed on a 50/50 cost and revenue share arrangement.
Rani Therapeutics secured approximately $10 million through a registered direct offering, which involved the sale of 3 million shares of Class A common stock and pre-funded warrants for 333,333 shares. The proceeds are expected to support the continued development of its RaniPill capsule technology.
H.C. Wainwright reaffirmed a Buy rating on Rani Therapeutics shares with a $9.00 price target, reflecting confidence in Rani's potential to impact the obesity treatment market with its novel drug delivery system.
Lastly, Rani Therapeutics appointed Marcum LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP, with no disagreements reported on matters of accounting principles, practices, financial statement disclosure, or auditing procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.